PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.\', \'Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.\', \'Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA.\', \'Oncology at MedImmune/AstraZeneca, Gaithersburg, MD, USA.\', \'Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.\', \'Service de Hematologie Seniors, Hospital Saint Louis, Universit Paris 7, Paris, France.\', \'Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA.\', \'Department of Medical Oncology, Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA.\', \'Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1080/10428194.2020.1791854
?:hasPublicationType
?:journal
  • Leukemia & lymphoma
is ?:pmid of
?:pmid
?:pmid
  • 32667230
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32667230>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32667230>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all